LiO-AD: Lithium Orotate in Alzheimers Disease Feasibility, Biomarker Engagement, and Clinical Response

Inclusion Criteria: * Diagnosis of Alzheimer's disease confirmed by biomarkers (imaging or biofluid evidence of amyloid-beta and tau pathology) * Mild stage of Alzheimer's disease: Clinical Dementia Rating (CDR) ≤ 1 or Quick Dementia Rating System (QDRS) ≤ 8 * Medically stable and able to attend study visits and complete study procedures * On stable doses of any psychotropic medications for at least 4 weeks before the baseline visit * Not currently receiving anti-amyloid monoclonal antibody therapy Exclusion Criteria: * New or unstable neurological disorder or unstable psychiatric illness that could affect safety or study results * Clinically significant kidney or thyroid problems that pose safety concerns, or abnormal safety labs judged to be related to study drug and requiring discontinuation * Use of thiazide diuretics during the dosing period (unless stopped at least 4 weeks before baseline) * Chronic daily use of non-aspirin NSAIDs (including COX-2 inhibitors); short courses require study team approval and may require temporary study drug hold and safety labs before resuming * Starting excluded therapies during the active treatment period (e.g., anti-amyloid monoclonal antibody treatment) * Noncompliance with essential study procedures that would prevent collection of primary safety or feasibility endpoints (e.g., repeated missed visits or refusal of critical labs)